StockNews.AI
KALV
StockNews.AI
35 days

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

1. KALV receives UK authorization for EKTERLY, the first oral treatment for HAE. 2. This milestone may significantly enhance KALV's market presence and sales potential.

2m saved
Insight
Article

FAQ

Why Very Bullish?

Approval of EKTERLY could lead to increased revenue and market share, reminiscent of similar past drug approvals boosting stock prices in biotech.

How important is it?

The approval directly enhances KALV's product pipeline and market strategy, making it highly impactful.

Why Long Term?

With successful commercialization, EKTERLY's market entry may generate sustained revenue growth over several years, much like other approved drugs in the sector.

Related Companies

BIIBALNYRGEN
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) has granted marketing authorization for EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor, for the treatment of hereditary angioedema (HAE) attacks in adults and adolescents aged 12 years and older. EKTERLY is the first and only oral on-demand treatment for HAE approved in t.

Related News